179 related articles for article (PubMed ID: 34963561)
1. CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.
Chiou JT; Huang CH; Wu TH; Wang LJ; Lee YC; Huang PW; Chang LS
Toxicol Appl Pharmacol; 2022 Jan; 435():115847. PubMed ID: 34963561
[TBL] [Abstract][Full Text] [Related]
2. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
[TBL] [Abstract][Full Text] [Related]
3. AMPK inhibition induces MCL1 mRNA destabilization via the p38 MAPK/miR-22/HuR axis in chronic myeloid leukemia cells.
Lee YC; Chiou JT; Chang LS
Biochem Pharmacol; 2023 Mar; 209():115442. PubMed ID: 36720359
[TBL] [Abstract][Full Text] [Related]
4. Hydroquinone-selected chronic myelogenous leukemia cells are sensitive to chloroquine-induced cytotoxicity via MCL1 suppression and glycolysis inhibition.
Chiou JT; Lee YC; Chang LS
Biochem Pharmacol; 2023 Dec; 218():115934. PubMed ID: 37989415
[TBL] [Abstract][Full Text] [Related]
5. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells.
Chiou JT; Lee YC; Huang CH; Shi YJ; Wang LJ; Chang LS
Toxicol Appl Pharmacol; 2020 Jan; 387():114857. PubMed ID: 31837377
[TBL] [Abstract][Full Text] [Related]
6. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.
Chiou JT; Chang LS
Apoptosis; 2024 Apr; 29(3-4):503-520. PubMed ID: 38066391
[TBL] [Abstract][Full Text] [Related]
7. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells.
Chiou JT; Lee YC; Wang LJ; Chang LS
Chem Biol Interact; 2022 Jul; 361():109978. PubMed ID: 35561756
[TBL] [Abstract][Full Text] [Related]
8. Carboxyl group-modified α-lactalbumin induces TNF-α-mediated apoptosis in leukemia and breast cancer cells through the NOX4/p38 MAPK/PP2A axis.
Chiou JT; Shi YJ; Lee YC; Wang LJ; Chen YJ; Chang LS
Int J Biol Macromol; 2021 Sep; 187():513-527. PubMed ID: 34310992
[TBL] [Abstract][Full Text] [Related]
9. LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
Han Y; Ma Z
Anticancer Drugs; 2021 Apr; 32(4):427-436. PubMed ID: 33587348
[TBL] [Abstract][Full Text] [Related]
10. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Inoue C; Sobue S; Kawamoto Y; Nishizawa Y; Ichihara M; Abe A; Hayakawa F; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2020 May; 525(4):1074-1080. PubMed ID: 32184020
[TBL] [Abstract][Full Text] [Related]
11. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
[TBL] [Abstract][Full Text] [Related]
12. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
14. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
Chiou JT; Wu YY; Lee YC; Chang LS
Biochem Pharmacol; 2023 Sep; 215():115738. PubMed ID: 37562509
[TBL] [Abstract][Full Text] [Related]
15. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Kosztyu P; Bukvova R; Dolezel P; Mlejnek P
Chem Biol Interact; 2014 Aug; 219():203-10. PubMed ID: 24954033
[TBL] [Abstract][Full Text] [Related]
16. Albendazole-Induced SIRT3 Upregulation Protects Human Leukemia K562 Cells from the Cytotoxicity of MCL1 Suppression.
Wang LJ; Liou LR; Shi YJ; Chiou JT; Lee YC; Huang CH; Huang PW; Chang LS
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486166
[TBL] [Abstract][Full Text] [Related]
17. Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells.
Chiou JT; Hsu CC; Hong YC; Lee YC; Chang LS
Biochem Pharmacol; 2023 May; 211():115494. PubMed ID: 36924905
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells.
Chiou JT; Lee YC; Huang CH; Wang LJ; Shi YJ; Chang LS
Biochem Pharmacol; 2021 Jun; 188():114544. PubMed ID: 33831396
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
20. Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway.
Lee YC; Chiou JT; Wang LJ; Chen YJ; Chang LS
Toxicol Appl Pharmacol; 2023 Sep; 474():116625. PubMed ID: 37451322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]